ADDISON, Texas, Jan. 8, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR) announced today the first shipment of the 0.75 gram blister pack to our Austrian marketing partner.
The extensive clinical experience in Austria has established a significant platform from which to rapidly penetrate this market. Both clinical and economic benefits have been established in the use of Altrazeal® in patients with acute and chronic wounds.
Commenting on the launch of Altrazeal® in Austria, Helmut Kerschbaumer, Chairman of Melmed Holding AG, stated, "We are excited to launch Altrazeal® in the first European market. Given the changes that are occurring in reimbursement in certain European markets this is an ideal time to launch this highly cost effective advanced wound care dressing. The clinical experience, particularly the Austrian experience which has been developed by important key opinion leaders, favourably positions Altrazeal® to compete for a leadership position in Austria and throughout Europe. The innovative packaging design of the 0.75 gram blister pack, which has been very positively received by the medical community, further improves Altrazeal's® ease of application and provides a highly innovative image reflecting the significant advancement Altrazeal® represents in the advanced wound care market."
Altrazeal® is an advanced scientifically engineered material that is unique in the field of advanced wound care dressings in terms of properties and performance. It incorporates the features and benefits of the desired "ideal" wound dressing. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers, pressure ulcers and geriatric wounds.
Mr. Kerschbaumer continued, "Significant interest has been expressed by multiple distribution partners in all the major European markets. We anticipate concluding additional partnerships and launching Altrazeal® in multiple European markets in the near future."
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the anticipated launch of Altrazeal® in Europe, the clinical and economic benefits of Altrazeal®, timing of Altrazeal® launch and ability to achieve a leadership market share. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's lack of profitability, the need for additional capital to operate its business, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
SOURCE ULURU Inc.